TY - JOUR
T1 - Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors
AU - O'Connor, Jeremy M.
AU - Seidl-Rathkopf, Kathi
AU - Torres, Aracelis Z.
AU - You, Paul
AU - Carson, Kenneth R.
AU - Ross, Joseph S.
AU - Gross, Cary P.
N1 - Publisher Copyright:
© AlphaMed Press 2018
PY - 2018/11
Y1 - 2018/11
N2 - Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti-PD1 agents), little is known about whether race- or sex-based disparities exist in their use. In this observational study, we constructed a large and mostly community-based cohort of patients with advanced stage cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, to compare the odds of receiving systemic treatment with or without anti-PD1 agents by race and by sex. In multivariable models that adjusted for age, stage, and number of prior anticancer therapies, we found no significant race-based disparities in anti-PD1 treatment. However, among patients with NSCLC, males had significantly higher odds of receiving anti-PD1 treatment compared with females (odds ratio 1.13, 95% confidence interval 1.02–1.24, p =.02). This finding suggests that as anti-PD1 agents enter the market to transform patient care, it will be critical to monitor for disparities in the use of these drugs.
AB - Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti-PD1 agents), little is known about whether race- or sex-based disparities exist in their use. In this observational study, we constructed a large and mostly community-based cohort of patients with advanced stage cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, to compare the odds of receiving systemic treatment with or without anti-PD1 agents by race and by sex. In multivariable models that adjusted for age, stage, and number of prior anticancer therapies, we found no significant race-based disparities in anti-PD1 treatment. However, among patients with NSCLC, males had significantly higher odds of receiving anti-PD1 treatment compared with females (odds ratio 1.13, 95% confidence interval 1.02–1.24, p =.02). This finding suggests that as anti-PD1 agents enter the market to transform patient care, it will be critical to monitor for disparities in the use of these drugs.
UR - http://www.scopus.com/inward/record.url?scp=85050920046&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2017-0673
DO - 10.1634/theoncologist.2017-0673
M3 - Article
C2 - 30012876
AN - SCOPUS:85050920046
SN - 1083-7159
VL - 23
SP - 1388
EP - 1390
JO - Oncologist
JF - Oncologist
IS - 11
ER -